TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
- Conditions
- Ovarian Neoplasms
- Registration Number
- NCT00057720
- Lead Sponsor
- Telik
- Brief Summary
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 440
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (270)
Little Rock Hematology Oncology Associates
🇺🇸Little Rock, Arkansas, United States
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States
Southern California Permanente Medical Group
🇺🇸San Diego, California, United States
Providence Saint Joseph Medical Center
🇺🇸Burbank, California, United States
Marilyn Norton, M. D.
🇺🇸Chula Vista, California, United States
Rosalba Rodriguez, M. D.
🇺🇸Chula Vista, California, United States
Bay Area Research Cancer Group
🇺🇸Concord, California, United States
Southwest Cancer Care
🇺🇸Poway, California, United States
California Oncology of the Central Valley
🇺🇸Fresno, California, United States
Kaiser Permanente Oncology Clinical Trials Program
🇺🇸Vallejo, California, United States
Scroll for more (260 remaining)Little Rock Hematology Oncology Associates🇺🇸Little Rock, Arkansas, United States